title: Evaluation of prognostic factors and survival results in pancreatic carcinomas in Turkey.
abstract: BACKGROUND
  The goal of this retrospective study was to evaluate patient characteristics, treatment modalities and prognostic factors in Turkish patients with pancreatic cancer.
  
  
  METHODS
  Between January 1997 and December 2012, 64 patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine with a diagnosis of pancreatic cancer were evaluated. The E/K ratio of the cases was 2.4/1 and the median age was 59.6 (32-80) years, respectively. Some 11 cases (18%) were stage 1, 21 (34.4%) were stage 2, 10 (16.4%) were stage 3, and 19 (31.1%) were metastatic.
  
  
  RESULTS
  The mean follow-up time was 15.7 months (0.7-117.5) and loco-regional recurrence was noted in 11 (40.7%) who underwent surgery while metastases were observed in 41 patients (66.1%). The median overall survival (OS) was 11.2 months and the 1, 3 and 5-year OS rates were 41.7%, 9.9% and 7.9% respectively. The median disease-free survival (DFS) was 5.2 month and the1, 2 and 5 year DFS were 22.6%, 7.6% and 3.8% respectively. On univariate analysis, prognostic factors affecting OS included status of the operation (p<0.001), tumor stage (p=0.008), ECOG performance status (p=0.005) and CEA level (p=0.017).On multivariate analysis, prognostic factors affecting survival included status of the operation (p=0.033) and age (p= 0.023).
  
  
  CONCLUSIONS
  In the current study, age and operation status were independent prognostic factors for overall survival with pancreatic patients. Thus, the patients early diagnosis and treatment ars essential. However, prospective studies with more patients are needed for confirmation.
authors.affiliation: Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey E-mail : dremocan@yahoo.com.
authors.forename: Emine
authors.initials: E
authors.lastname: Canyilmaz
authors.forename: Lasif
authors.initials: L
authors.lastname: Serdar
authors.forename: Gonca Hanedan
authors.initials: GH
authors.lastname: Uslu
authors.forename: Gulsen
authors.initials: G
authors.lastname: Soydemir
authors.forename: Zumrut
authors.initials: Z
authors.lastname: Bahat
authors.forename: Adnan
authors.initials: A
authors.lastname: Yoney
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D015996:Survival Rate; D014421:Turkey